Small Cap Feast

15th May 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings: 





Whats baking in the oven?

Potential Initial Public Offerings:

7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has announced its intention to seek Admission to trading on the Aquis Stock Exchange Growth Market. The Company reports it is revenue generating, profitable in FY23, with £1.9m cash in the bank at 31st March 2024. The Company's application to the AQSE Growth Market is not conditional on it raising funds. However, the Company is seeking to raise up to £1m of new money to de-risk growth and in support of its strategy of coupling organic growth and acquisition.

15th May: Raspberry Pi, a company involved in low-cost, high-performance computing announces that it is considering an IPO onto the premium listing segment of the Main Market. Raspberry Pi is a designer and developer of high-performance, low-cost single board computers and compute modules for industrial IoT customers and embedded uses, as well as for enthusiasts and educators, in markets worldwide. In the years ended 31 December 2021, 2022, and 2023, the Group's revenue was $140.6m, $187.9m and $265.8m, respectively. Gross profit was $41.9m, $42.3m and $66.0m


Reverse Takeovers:

13th May: Amur Minerals Corporation announced that the Company has executed a sale and purchase agreement to conditionally acquire the entire issued and to be issued share capital of Extruded Pharmaceuticals, a UK-based drug delivery technology company focused on the local delivery of chemotherapy drugs, for an aggregate consideration of £5.5m. The reverse takeover is awaiting the approval of Shareholders at a General Meeting on 29 May.


Change of Market:

Dual Listing :


Banquet Buffet

4Global 54p £14.2m (4GBL.L)

The data and technology company focused on providing customers in the sport and fitness sector with business-critical insights about their customers, operations, and investments announces a trading update for the year ended 31 March 2024. The Company is expected to report revenues up 15% to £6.4m (2023: £5.6m), EBITDA expected to increase 30% to £1.6m (2023: £1.2m) and the cash balance at 31 March 2024 is £0.2m. Market guidance for FY24/25 will be given at the time of our final audited results announcement, expected in July in line with previous years.

Atlantic Lithium 22.4p £145.5m (ALL.L)

The African-focused lithium exploration and development company targeting to deliver Ghana's first lithium mine announces the appointment of Edward Nana Yaw Koranteng to the Company's Board of Directors as Independent Non-Executive Director, effective immediately. Edward Koranteng is a lawyer and an experienced corporate and investment banker with over 23 years of experience. He has held the position of Chief Executive Officer of the Minerals Income Investment Fund, Ghana's sovereign minerals wealth fund, since 2021. As CEO, he oversees the management of Ghana's equity interest in mining companies, manages all royalties paid to the state from mining activities and supports the growth of the mining industry through long-term, sustainable investments in the sector.

Creo Medical Group 32.5p £117.5m (CREO.L)

The medical device company focused on the emerging field of surgical endoscopy announces its audited final results for the 12 months ended 31 December 2023. Revenue increased to £30.8m (2022: £27.2m), operating loss was reduced to £24.8m (2022: £30.7m) and the cash balance was £17.4m (2022: £13.1m). Over the next six to 12 months, the Company looks forward to another year of strong growth in core technology from both existing and new users, helping them drive towards the goal of self-sustaining cashflows.

DSW Capital 47p £10.3m (DSW.L)

The challenger professional services licence network and owner of Dow Schofield Watts brand, announces the following trading update ahead of its final results for the year ended 31 March 2024. Revenue expected to be £16.0m (2023: £18.3m), Adjusted pre-tax profit expected to be £0.5m (2023: £1.4m) and cash balance of £2.6m (2023: £4.6m). The Board remains confident in the long-term prospects for the business and continues to add new Partners and new licensee businesses to fuel future growth.

European Green Transition 16.25p £23.5m (EGT.L)

The Company developing green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition announces further results from recent channel and grab sampling at the Djupedal prospect within the Olserum Rare Earth Elements (REE) project located in south Sweden. Channel samples taken over a 100 metre zone at Djupedal confirm REE mineralisation including three metres grading 1.58% TREO and one metre grading 2.27% TREO with c. 30% HREO average. Encouraging results support Directors' belief that the Company's fully permitted low-cost drill programme scheduled for H2-2024 could confirm project upside, supporting the aim of attracting a partner to fund a larger scale, fully permitted programme.

Global Connectivity * 0.65p £2.4m (AQSE: GCON)

The Company focused on communication services and technologies that enhance connectivity announces its final and audited full year 2023 financial results to 31 December 2023. Cash balances were up to £0.46m, bolstered by the full and final settlement of the intercompany debt paid early and in full by Rural Broadband Solutions Holdings Limited in which Global Connectivity has a 15% stake. Current assets including cash were up by £0.88m to £1.5m largely because of unpaid share subscriptions relating to three individuals who brought Rural Broadband Solutions plc as an entity together reversing it into SAPO plc in October 2021, which are now falling into the current assets' category. In September 2023, Macquarie Capital, the Israel Infrastructure Fund and Tiger Infrastructure Partners merged SWS Broadband and Cadence Networks with Voneus Broadband, and simultaneously acquired Broadway Partners. SWS Broadband, Cadence Networks and Broadway Partners all began operating as part of Voneus. The combined group will be funded with up to £250m in new capital from the three institutional shareholders and senior credit lenders to advance the Company's growth.

Griffin Mining 149.5p £275.5m (GFM.L)

The mining Company announces its annual report and accounts for the year ended 31 December 2023. Revenues have increased to $146.02m (2022: $94.40m), profit before tax increased to $24.49m (2022: $15.27m) and a cash balance of $60m (2022: $34.14m). Plus a record amounts of ore were mined, hauled and processed in 2023, with throughput reaching mill name plate capacity of 1.5m tonnes per annum, resulting in record zinc metal in concentrate production.

itim Group 39.5p £12.3m (ITIM.L)

The SaaS based technology company that enables store-based retailers to optimise their businesses to improve financial performance announces that it has signed a five year multi-million-pound contract renewal with Majestic Wine, the UKs largest specialist retailer with over 200 stores. The subscription renewal for itim's UNIFY platform supports retail, B2B and direct to consumer sales covering processes such as EPOS, e-commerce, PIM, stock management, merchandising, supplier management, pricing and promotions, customer order management, customer management, B2B customer accounts and website & business intelligence. UNIFY provides a single view of customer, product and real time stock across all channels.

Titon Holdings 75p £8.4m (TON.L)

The international manufacturer and supplier of ventilation systems and window and door hardware, today announces its unaudited interim results for the six months ended 31 March 2024. Revenue declined 24.6% to £9.1m (2023: £12.1m), EBITDA loss of £0.25m (2023: profit £0.1m) and a cash balance of £2.2m (2023: £1.6m). The Board remains committed to developing and executing its strategy to turn around performance and continues to focus on managing the cost base and improving efficiency.

ValiRx 2.2p £2.9m (VAL.L)

The life science company focusing on early-stage cancer therapeutics and women's health announces its audited results for the year ended 31 December 2023. Research and developments costs decreased to £383k (2022: £551k), total comprehensive loss of £2.04m (2022: £2.37m) and a cash balance of £174k (2022: £1.1m). 2024 will see another year of significant evolution, with the changes to the Board composition providing an opportunity to harness new expertise and skills into the Group, enabling further honing of the strategy to promote growth and development across all strands of the portfolio.

.

15 May 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram